Sanofi SA is to divest its consumer healthcare business unit in order to concentrate its development and commercialisation resources on innovative, proprietary medicines. This follows a similar decision by GSK Plc which also spun out its consumer products business into a separate, listed business in 2022. Sanofi announced the decision on 27 October, saying that the undertaking would most likely involve a capital markets transaction and could take place as early as the fourth quarter of 2024.
